📚 Wiki Weight Loss & Metabolic Mazdutide

Mazdutide

◉ Phase III (China)
Mazdutide (IBI362), GLP-1/Glucagon Dual Agonist
Also known as: IBI362, OXM-3, GLP-1/glucagon dual agonist
Brand names: Mazdutide (Innovent Biologics)
Page last reviewed

Quick Summary

Mazdutide (IBI362) is a once-weekly GLP-1/glucagon receptor dual agonist developed by Innovent Biologics. By activating both receptors simultaneously, it combines the appetite suppression and insulin-sensitizing effects of GLP-1 agonism with the fat-oxidizing and energy-expenditure-boosting effects of glucagon signaling.

Metabolic & Mitochondrial Phase III (China)
Mazdutide (IBI362) is a once-weekly GLP-1/glucagon receptor dual agonist developed by Innovent Biologics. By activating both receptors simultaneously, it combines the appetite suppression and insulin-sensitizing effects of GLP-1 agonism with the fat-oxidizing and energy-expenditure-boosting effects of glucagon signaling. Phase III trials in China showed ~15–17% weight loss at 9 mg over 36 weeks. It is being positioned as a competitor to tirzepatide and semaglutide in the Asian market.
Storage Stability
Lyophilized
6–12 months (2–8°C)
Reconstituted
~30 days (2–8°C)
Room temp
Avoid

Mechanism of Action

GLP-1 Component

GLP-1 receptor activation reduces appetite, slows gastric emptying, stimulates glucose-dependent insulin secretion, and suppresses glucagon from pancreatic alpha cells.

Glucagon Component

Glucagon receptor activation increases hepatic glucose output (managed by co-existing GLP-1 suppression), promotes lipolysis in adipose tissue, and increases resting energy expenditure through thermogenesis, mechanisms that amplify fat loss beyond GLP-1 alone.

Dual Receptor Balance

The key design challenge of dual agonists: glucagon's hyperglycemic effects are offset by simultaneous GLP-1 receptor activation. The 1:1 or weighted balance in the molecule determines net glycemic impact.

Research Summary

Phase III GLORY Trial (China)

In 568 obese Chinese adults, mazdutide 6 mg and 9 mg weekly for 36 weeks produced 14.4% and 15.8% body weight loss respectively, vs. 2.0% with placebo. Significant improvements in metabolic markers including waist circumference, blood pressure, and lipids.

T2DM Sub-Group

In patients with type 2 diabetes, mazdutide reduced HbA1c by 1.7% with the 6 mg dose.

vs. Western Competitors

Mazdutide's weight loss (~15–17%) sits between semaglutide (~15%) and tirzepatide (~20–22%). Its differentiation is the glucagon receptor activity which may offer metabolic advantages in NAFLD/MASH.

Calculate your Mazdutide dose Vial strength, BAC water, exact syringe draw in IU. Free, no signup. Open Calc →

Research Protocols

Titration

Start at 3 mg weekly for 4 weeks, increase to 6 mg for 4 weeks, then 9 mg maintenance if tolerated. GI side effects peak during titration.

Injection

Subcutaneous injection once weekly. Abdomen, thigh, or upper arm. Rotate sites.

Storage & Handling

Refrigerate at 2–8°C. Do not freeze. Protect from light. Can be kept at room temperature (<30°C) for limited period per manufacturer guidance.


References

  • [1]Ji L, et al. "Mazdutide for obesity in Chinese adults (GLORY): Phase 3 RCT." Nat Med, 2024.
  • [2]Lv W, et al. "IBI362, a GLP-1/glucagon receptor dual agonist, for T2DM and obesity." J Diabetes, 2023.
Ready to dose Mazdutide?
Get the exact syringe draw
You have read the research. Now run the math. Pick your vial size and BAC water volume, get IU draw in seconds.
Open the Calculator →
Verified Scientific Data Last audited:
Data Sources & External References
Source: peer-reviewed literature  ·  Domain: ascendpeptide.org
Mazdutide
Peptide calculator, vial + dose → draw volume
Dose Mazdutide →

Suggest a Change

Mazdutide · wiki page